Targeting C-reactive protein for the treatment of cardiovascular disease.
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Complement-mediated inflammation exacerbates the tissue injury of ischaemic necrosis in heart attacks and strokes, the most common causes of death in developed countries. Large infarct size increases immediate morbidity and mortality and, in survivors of the acute event, larger non-functional scars adversely affect long-term prognosis. There is thus an important unmet medical need for new cardioprotective and neuroprotective treatments. We have previously shown that human C-reactive protein (CRP), the classical acute-phase protein that binds to ligands exposed in damaged tissue and then activates complement, increases myocardial and cerebral infarct size in rats subjected to coronary or cerebral artery ligation, respectively. Rat CRP does not activate rat complement, whereas human CRP activates both rat and human complement. Administration of human CRP to rats is thus an excellent model for the actions of endogenous human CRP. Here we report the design, synthesis and efficacy of 1,6-bis(phosphocholine)-hexane as a specific small-molecule inhibitor of CRP. Five molecules of this palindromic compound are bound by two pentameric CRP molecules, crosslinking and occluding the ligand-binding B-face of CRP and blocking its functions. Administration of 1,6-bis(phosphocholine)-hexane to rats undergoing acute myocardial infarction abrogated the increase in infarct size and cardiac dysfunction produced by injection of human CRP. Therapeutic inhibition of CRP is thus a promising new approach to cardioprotection in acute myocardial infarction, and may also provide neuroprotection in stroke. Potential wider applications include other inflammatory, infective and tissue-damaging conditions characterized by increased CRP production, in which binding of CRP to exposed ligands in damaged cells may lead to complement-mediated exacerbation of tissue injury.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Heuristics may lead to bias or predictable and systematic cognitive errors, as described in Table 2.16,35”
From Artificial Intelligence and Surgical Decision-making. (2020) · cites this paper as [54]
Citations
Cites
PROCHECK: a program to check the stereochemical quality of protein structures
Laskowski, R. A., MacArthur, M. W., Moss, D. S., & Thornton, J. M. (1993) · Journal of Applied Crystallography · doi:10.1107/s0021889892009944 · Cited by 24,581
The CCP4 suite: programs for protein crystallography
Collaborative Computational Project, N. 4. (1994) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444994003112 · Cited by 17,270
Crystallography & NMR System: A New Software Suite for Macromolecular Structure Determination
Brünger, A. T., Adams, P. D., Clore, G. M., DeLano, W. L., Gros, P., Grosse-Kunstleve, R. W., Jiang, J. S., Kuszewski, J., Nilges, M., Pannu, N. S., et al. (1998) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444998003254 · Cited by 15,715
Refinement of Macromolecular Structures by the Maximum-Likelihood Method
Murshudov, G. N., Vagin, A. A., & Dodson, E. J. (1997) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444996012255 · Cited by 14,742
MOLREP: an Automated Program for Molecular Replacement
Vagin, A., & Teplyakov, A. (1997) · Journal of Applied Crystallography · doi:10.1107/s0021889897006766 · Cited by 4,714
C-reactive protein: a critical update
Pepys, M. B., & Hirschfield, G. M. (2003) · Journal of Clinical Investigation · doi:10.1172/jci18921 · Cited by 3,503
Self-citationWHAT IF: A molecular modeling and drug design program
Vriend, G. (1990) · Journal of Molecular Graphics · doi:10.1016/0263-7855(90)80070-v · Cited by 3,469
C-reactive protein: a critical update
Pepys, M. B., & Hirschfield, G. M. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200318921 · Cited by 3,436
Self-citationThe integration of macromolecular diffraction data
Leslie, A. G. W. (2006) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444905039107 · Cited by 1,341
The physiological structure of human C-reactive protein and its complex with phosphocholine
Thompson, D., Pepys, M. B., & Wood, S. P. (1999) · Structure · doi:10.1016/s0969-2126(99)80023-9 · Cited by 818
Self-citation
Cited by
Items 401–500 of 670
Complement-pentraxins synergy: Navigating the immune battlefield and beyond
Ma, Y. J., Parente, R., Zhong, H., Sun, Y., Garlanda, C., & Doni, A. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115878 · Cited by 16
Tachibana, A., Iga, J., Ozaki, T., Yoshida, T., Yoshino, Y., Shimizu, H., Mori, T., Furuta, Y., Shibata, M., Ohara, T., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-57922-1 · Cited by 18
“Serum high-sensitivity C reactive protein (hs-CRP) is a conveniently measured biomarker of systemic inflammation 10 , but there is no consensus on the association between serum hs-CRP and dementia including AD.”
BackgroundKarasu, E., Halbgebauer, R., Schütte, L. D., Greven, J., Bläsius, F., Zeller, J., Winninger, O., Braig, D., Messerer, D. A. C., Berger, B., et al. (2025) · BMC Biology · doi:10.1186/s12915-024-02093-8 · Cited by 16
“To prevent pCRP dissociation and downstream inflammatory effects, we included 1,6-bis(phosphocholine)-hexane (1,6-bis-PC) [12].”
InfluentialLee, B. S., Kim, S. H., Oh, J., Jin, T., Choi, E. Y., Park, S., Lee, S., Chung, J. H., & Kang, S. (2014) · PLoS ONE · doi:10.1371/journal.pone.0098113 · Cited by 16
“Furthermore, several reports from several cell types suggest that CRP is a key role in cell differentiation and cell cycle [1,7,9,20].”
BackgroundSerrano, N. C., Guío, E., Becerra‐Bayona, S. M., Quintero-Lesmes, D. C., Bautista‐Niño, P. K., Colmenares-Mejía, C., Páez, M. C., Luna-González, M., Díaz‐Martínez, L. A., Ortiz, R., et al. (2020) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.1080/00365513.2020.1747110 · Cited by 17
“As a result, CRP and IL-6 molecules may be potential therapeutic targets of pre-eclampsia prevention and interventions that modify their maternal serum concentration, only if their causal role is proved [32].”
BackgroundMasugata, H., Senda, S., Inukai, M., Murao, K., Tada, S., Hosomi, N., Iwado, Y., Noma, T., Kohno, M., Himoto, T., et al. (2011) · The Tohoku Journal of Experimental Medicine · doi:10.1620/tjem.223.263 · Cited by 16
“Thus, hsCRP has been well used recently as an interesting therapeutic target for the prevention of cardiovascular disease (Pepys et al. 2006).”
BackgroundAssociation between arterial stiffness and pulmonary function in hypertensive patients
Masugata, H., Senda, S., Okada, H., Murao, K., Inukai, M., Himoto, T., Hosomi, N., Murakami, K., Noma, T., Kohno, M., et al. (2011) · Hypertension Research · doi:10.1038/hr.2011.199 · Cited by 17
Chen, R., Qi, J., Yuan, H., Wu, Y., Hu, W., & Xia, C. (2015) · Journal of Structural Biology · doi:10.1016/j.jsb.2015.01.001 · Cited by 16
“Currently, CRP and SAP are extensively used as biomarkers of various diseases and are targeted in cardiovascular disease treatment (Pepys et al., 2006).”
BackgroundClinical Significance of High-Sensitivity C-Reactive Protein in Cardiovascular Disease
Conen, D., & Ridker, P. M. (2007) · Biomarkers in Medicine · doi:10.2217/17520363.1.2.229 · Cited by 18
Linker-mediated assembly of gold nanoparticles into multimeric motifs
Sikora, M., Szymczak, P., Thompson, D., & Cieplak, M. (2011) · Nanotechnology · doi:10.1088/0957-4484/22/44/445601 · Cited by 16
“also be used as a risk factor for future coronary heart disease or stroke [52, 53].”
BackgroundSelf-citationIn Situ Probing Unusual Protein Adsorption Behavior on Electrified Zwitterionic Conducting Polymers
Wu, J., Wei, S., & Luo, S. (2020) · Advanced Materials Interfaces · doi:10.1002/admi.202000470 · Cited by 16
The Relationship Between Serum Bilirubin Concentration and Atrial Fibrillation
Demir, M. (2013) · Cardiology Research · doi:10.4021/cr299w · Cited by 16
C-reactive protein and subclinical cardiovascular disease among African−Americans
Sung, J. H., Lee, J. E., Samdarshi, T. E., Nagarajarao, H. S., Taylor, J. K., Agrawal, K., Taylor, H. A., & Fox, E. R. (2014) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0b013e32836411d6 · Cited by 16
Article Commentary: Serum C-Reactive Protein (CRP), Target for Therapy or Trouble?
Kraus, V. B., & Jordan, J. M. (2006) · Biomarker Insights · doi:10.1177/117727190600100020 · Cited by 16
“A small-molecule inhibitor of CRP, perhaps the fi rst of many to come, has recently been designed and synthesized (Pepys et al. 2006).”
BackgroundKurl, S., Jae, S. Y., Voutilainen, A., & Laukkanen, J. A. (2021) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2021.04.004 · Cited by 16
Tong, C., & Zhou, B. (2024) · Journal of Molecular and Cellular Cardiology Plus · doi:10.1016/j.jmccpl.2024.100278 · Cited by 32
Molecular and histological effects of MR-guided pulsed focused ultrasound to the rat heart
Jang, K. W., Tu, T., Nagle, M. E., Lewis, B. K., Burks, S. R., & Frank, J. A. (2017) · Journal of Translational Medicine · doi:10.1186/s12967-017-1361-y · Cited by 15
CRP gene polymorphism predicts post-stroke functional outcome in Han Chinese
Guo, J., Yu, L., Zhang, J., Chen, N., Zhou, M., & He, L. (2013) · Acta Neurologica Scandinavica · doi:10.1111/ane.12180 · Cited by 15
“ischemia, as recent studies have shown that CRP can bind to ligands exposed in damaged tissue and can then activate complement-mediated exacerbation of tissue injury (23, 24).”
BackgroundLorenzo, A. D., Pittella, F. J. M., & da Rocha, A. S. C. (2012) · Inflammation · doi:10.1007/s10753-011-9426-1 · Cited by 15
“A few studies have reported the use of statins [22, 23], but no definitive evidence exists yet.”
BackgroundC-Reactive Protein and Prognosis in Diabetes: Getting to the Heart of the Matter
Sattar, N. A., & Hingorani, A. D. (2009) · Diabetes · doi:10.2337/db08-1788 · Cited by 15
“In summary, therefore, although CRP commands much interest as a CVD risk factor, higher-resolution observational epidemiology (such as that in the Emerging Risk Factors Collaboration [5]), continued genetic epidemiology, and eventually specific CRP inhibitors (20) are needed to help the vascular risk community make a…”
BackgroundBasu, A., Sing, S., Das, A., Jana, G., & Samai, B. (2023) · Journal of Photochemistry and Photobiology A Chemistry · doi:10.1016/j.jphotochem.2023.114996 · Cited by 14
Deng, S., Wu, J., Zhang, K., Li, Y., Yang, L., Hu, D., Jin, Y., Hao, Y., Wang, X., Liu, Y., et al. (2019) · Analytical Chemistry · doi:10.1021/acs.analchem.9b02427 · Cited by 14
Targeting conformational changes in C‐reactive protein to inhibit pro‐inflammatory actions
Filep, J. G. (2022) · EMBO Molecular Medicine · doi:10.15252/emmm.202217003 · Cited by 14
“In 2006, the Pepys group developed bivalent compounds, such as 1,6-bis(phosphocholine)-hexane (bis-PC) that bridges the PC-binding pockets on the B-face of two separate CRP pentamers, bringing the PC-binding surfaces (i.e., the B-face) together in a parallel fashion (Pepys et al , 2006).”
Determination of inflammatory biomarkers in patients with COPD: a comparison of different assays
López-Campos, J. L., Arellano, E., Calero, C., Delgado, A., Martín, E. M., Cejudo, P., Ruiz, F. Ó., Rodríguez‐Panadero, F., & Montes‐Worboys, A. (2012) · BMC Medical Research Methodology · doi:10.1186/1471-2288-12-40 · Cited by 14
“[23], and CRP has recently become a therapeutic target in cardiovascular diseases [24].”
BackgroundSingh, S. K., Suresh, M. V., Prayther, D., Moorman, J. P., Rusiñol, A. E., & Agrawal, A. C. (2008) · Clinica Chimica Acta · doi:10.1016/j.cca.2008.04.015 · Cited by 14
Altered Binding of a Multimeric Protein by Changing the Self-Assembling Properties of its Substrate
Rosenzweig, B. A., Ross, N. T., Adler, M. J., & Hamilton, A. D. (2010) · Journal of the American Chemical Society · doi:10.1021/ja100485n · Cited by 15
Feng, Y., Liu, Y., Wang, D., Zhang, X., Liu, W., Fu, F., Dong, L., Zhang, H., Li, J., & Gao, F. (2013) · Critical Care Medicine · doi:10.1097/ccm.0b013e318278b6e7 · Cited by 17
Flores, M., Barquera, S., Carrión, C., Rojas, R., Villalpando, S., Olaiz-Fernández, G., & González‐Villalpando, C. (2007) · Salud Pública de México · doi:10.1590/s0036-36342007000900006 · Cited by 16
Liou, H. (2012) · The Chinese Journal of Physiology · doi:10.4077/cjp.2012.baa028 · Cited by 14
Holt, C. B., Thiel, S., Munk, K., Østergaard, J. A., Bøtker, H. E., & Hansen, T. K. (2013) · European Heart Journal Acute Cardiovascular Care · doi:10.1177/2048872613507004 · Cited by 14
Label-Free MIP Sensors for Protein Biomarkers
Jetzschmann, K. J., Zhang, X., Yarman, A., Wollenberger, U., & Scheller, F. W. (2017) · Springer series on chemical sensors and biosensors · doi:10.1007/5346_2017_3 · Cited by 16
Zeng, Q., Zeng, Y., SLEVIN, M. A., Guo, B., Shen, Z., Deng, B., & Zhang, W. (2021) · BioMed Research International · doi:10.1155/2021/6671043 · Cited by 16
“In addition, in a rat model of acute myocardial infarction, artificial injection of CRP increased infarct size and exacerbated cardiac insufficiency, whereas the use of CRP inhibitors eliminated this effect [32].”
BackgroundInflammation and arterial function☆
Aznaouridis, K. A., & Stefanadis, C. (2007) · Artery Research · doi:10.1016/j.artres.2007.03.005 · Cited by 19
Chemical knockout of C-reactive protein in cardiovascular disease
Heinecke, J. W. (2006) · Nature Chemical Biology · doi:10.1038/nchembio0606-300 · Cited by 14
Ciurtin, C., Helmy, G., Ferreira, A. C., Manson, J. J., Jury, E. C., & McDonnell, T. C. R. (2024) · Clinical Immunology · doi:10.1016/j.clim.2024.110281 · Cited by 14
“Conversely, Peyps et al. (2006) found that inhibition of the dissociation to mCRP from pCRP was cardio-toxic using biochemical cross-linking of the pCRP monomers in a mouse model to alter the cardiovascular effects of mCRP [13].”
Vincensi, C. F., Lissarassa, Y. P. S., dos Santos, A. B., Beber, L. C. C., Sulzbacher, L. M., Goettems-Fiorin, P. B., Heck, T. G., Frizzo, M. N., & Ludwig, M. S. (2021) · Journal of Diabetes Research · doi:10.1155/2021/3314871 · Cited by 15
“Besides, considering that the wellrecognized inflammatory biomarker CRP [36, 37, 48] was not responsive in our study, we also suggest that in menopause plus diabetes low-grade inflammatory background, the serum eHSP72 levels may be more sensitive and a better biomarker of the preclinical stages.”
BackgroundInfluentialRegulatory Mechanisms Controlling Inflammation and Synthesis of Acute Phase Proteins
Jura, J., & Koj, A. (2011) · InTech eBooks · doi:10.5772/18207 · Cited by 14
Human C-reactive protein accentuates macrophage activity in biobreeding diabetic rats
Jialal, I., Kaur, H., & Devaraj, S. (2012) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2012.03.020 · Cited by 13
“In fact, in a rat model a small molecular inhibitor to hCRP was shown to prevent the induction an increase in myocardial infarct size with hCRP (Pepys et al., 2006).”
BackgroundMethodInfluentialC-reactive protein induces p53-mediated cell cycle arrest in H9c2 cardiac myocytes
Choi, J.-W., Lee, K. H., Kim, S. H., Jin, T., Lee, B. S., Oh, J., Won, H.-Y., Kim, S. Y., Kang, S., & Chung, J. H. (2011) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2011.06.016 · Cited by 13
Kim, K. H., Kim, W., Kang, W. Y., Hwang, S. H., Cho, S. C., Kim, W., Jeong, M. H., & Other Korean Working Group in Myocardial Infarction Investigators (2013) · Korean Circulation Journal · doi:10.4070/kcj.2013.43.10.664 · Cited by 15
Endothelial C-reactive protein increases platelet adhesion under flow conditions
Grad, E., Pachino, R. M., & Danenberg, H. D. (2011) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00067.2011 · Cited by 13
“Furthermore, CRP was found to be a valid target in reducing cardiovascular morbidity in an acute myocardial infarction model (24).”
BackgroundInsights into the mechanism of how Morin suppresses amyloid fibrillation of hen egg white lysozyme
Chong, X., Sun, L., Sun, Y., Chang, L., Chang, A. K., Lu, X., Zhou, X., Liu, J., Zhang, B., Jones, G. W., et al. (2017) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2017.03.107 · Cited by 13
Park, P. G., Song, J. J., Park, Y., & Lee, S. (2022) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.24237 · Cited by 13
Kwok, S., Canoy, D., Ashton, W. D., Lowe, G. D. O., Wood, D., Humphries, S. E., Charlton-Menys, V., & Durrington, P. N. (2009) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2009.03580.x · Cited by 14
Chakraborty, C., & Agrawal, A. C. (2013) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-013-9553-4 · Cited by 13
“infarction, a disease in which phosphocholine-bound CRPmediated complement activation worsens the condition [18].”
Use of Insulin to Improve Glycemic Control in Diabetes Mellitus
Dandona, P., Chaudhuri, A., Ghanim, H., & Mohanty, P. (2008) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-008-6101-3 · Cited by 14
“CRP may have an important and independent role in the pathogenesis of infarct size since the injection of CRP in experimental myocardial infarction has been shown to increase the size of the infarct [57] and small molecules specifically synthesized to bind CRP and to block its action reduce the size of the infarct [ 5…”
BackgroundC-reactive protein—does it promote vascular disease?*
Stenvinkel, P. (2006) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfl317 · Cited by 13
“Potential applications may include any inflammatory and/or infective conditions in which binding of CRP to exposed ligands in damaged cells may lead to complement-mediated exacerbation of tissue injury [12].”
BackgroundInfluentialLiu, X., Shi, X., Zhang, D., Zhao, S., Hu, J., Ouyang, Q., Yin, J., Yao, X., Zhang, Y., & Yan, L. (2025) · Composites Part B Engineering · doi:10.1016/j.compositesb.2025.112260 · Cited by 12
Nauser, C. L., & Sacks, S. H. (2022) · Immunological Reviews · doi:10.1111/imr.13144 · Cited by 13
Ferrara, F., Zeisig, V., Pietsch, S., Rütten, R., Dreyer, A. Y., Pieper, L., Schatzl, A.-K., McLeod, D. D., Barthel, H., Boltze, J., et al. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00272 · Cited by 12
Artificial intelligence and perioperative medicine
Bignami, E. G., Cozzani, F., RIO, P. D., & Bellini, V. (2020) · Minerva Anestesiologica · doi:10.23736/s0375-9393.20.14999-x · Cited by 17
Potempa, L. A., Qiu, W. Q., Stefanski, A., & Rajab, I. M. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.979461 · Cited by 13
“Habersberger’s group also showed that formation of mCRP from pCRP on a membrane surface could be prevented if pCRP was first neutralized by a bivalent bis-PC compound that links two juxtaposed pentamers (92).”
BackgroundChen, Z., Zhu, C., Yang, J., Zhang, M., Yuan, J., Shen, Y., Zhou, J., Huang, H., Xu, D., Crommen, J., et al. (2023) · Analytical Chemistry · doi:10.1021/acs.analchem.2c05683 · Cited by 12
Wang, Y., Wang, Y., You, S., Wang, H., Yin, D., Dou, K., & Song, W. (2016) · Chinese Medical Journal · doi:10.4103/0366-6999.192778 · Cited by 13
“[22] Finally, the therapeutic inhibition of CRP could counteract the increase in infarct size and cardiac dysfunction produced by the injection of human CRP in rats.[23] Thus, CRP might play a role in the progression of CAE.”
BackgroundChen, L., Wei, B., Xu, L., & Wu, Y. (2017) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2017.10.008 · Cited by 12
C‐Reactive Protein: From Biomarker to Trigger of Cell Death?
Kunze, R. (2019) · Therapeutic Apheresis and Dialysis · doi:10.1111/1744-9987.12802 · Cited by 12
Wu, Y., Zheng, G., Zhang, F., & Li, W. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1544917 · Cited by 13
Cationic polymer-based plasmonic sensor array that discriminates proteins
Xi, H., Li, X., Liu, Q., & Chen, Z. (2018) · The Analyst · doi:10.1039/c8an01360h · Cited by 11
Proteína C reactiva: aspectos cardiovasculares de una proteína de fase aguda
Amezcua-Guerra, L. M., del Villar, R. S., & Bojalil, R. (2007) · REMERI - Red Mexicana de Repositorios Institucionales · Cited by 11
Šilhavý, J., Zídek, V., Landa, V., Šimáková, M., Mlejnek, P., Škop, V., Oliyarnyk, O., Kazdová, L., Mancini, M., Saar, K., et al. (2014) · Cardiovascular Therapeutics · doi:10.1111/1755-5922.12061 · Cited by 11
“Although mouse models are available that transgenically express human CRP, we chose to study the rat because of suggestions that the rat may be a more suitable model for investigating adverse biological actions of human CRP [14,15].”
BackgroundGenetically elevated C-reactive protein and ischemic vascular disease
Liao, J. K. (2009) · Current Atherosclerosis Reports · doi:10.1007/s11883-009-0038-2 · Cited by 11
“Although some experimental and clinical studies suggest that high levels of exogenous CRP could impair vascular function [3,4], it is not known whether CRP is truly a mediator of cardiovascular disease.”
BackgroundGenistein alters coagulation gene expression in ovariectomised rats treated with phytoestrogens
Kelly, L. A., O’Leary, J. J., Seidlová‐Wuttke, D., Wuttke, W., & Norris, L. (2010) · Thrombosis and Haemostasis · doi:10.1160/th10-03-0201 · Cited by 11
“CRP is a risk marker for cardiovascular disease and recent studies have identified it as a possible target for use in primary prevention (31).”
BackgroundKim, C., Kwon, K., Lee, J. C., Kim, H., Chae, K. H., & Ree, M. (2017) · Macromolecules · doi:10.1021/acs.macromol.7b00805 · Cited by 11
C-Reactive Protein Causes Blood Pressure Drop in Rabbits and Induces Intracellular Calcium Signaling
Bock, C., Vogt, B., Mattecka, S., Yapici, G., Brunner, P., Fimpel, S., Unger, J. K., & Sheriff, A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01978 · Cited by 12
Chan, J. E., Mann, A. K., Kapp, D. S., & Rehkopf, D. H. (2020) · BMC Public Health · doi:10.1186/s12889-020-09923-8 · Cited by 14
Das, U. N. (2011) · Springer eBooks · doi:10.1007/978-94-007-0495-4_3 · Cited by 12
CRP-Apherese bei akutem Myokardinfarkt bzw. COVID-19
Buerke, M., Sheriff, A., & Garlichs, C. D. (2022) · Medizinische Klinik - Intensivmedizin und Notfallmedizin · doi:10.1007/s00063-022-00911-x · Cited by 13
“Die Rolle von CRP als Mediator von Gewebeschädigungen ist lange vernachlässigt worden, auch wenn es hierfür seit Langem deutliche Hinweise bei einigen Tierspezies gab [3, 49, 64, 72].”
BackgroundKitagawa, M., Haji, S., & Amagai, T. (2017) · In Vivo · doi:10.21873/invivo.11161 · Cited by 15
Wang, Z., Xiong, F., Zhang, Q., & Wang, H. (2024) · Aging Clinical and Experimental Research · doi:10.1007/s40520-024-02865-w · Cited by 10
“Chronic inflammation plays a crucial role in the develop - ment and progression of many chronic illnesses, includ - ing cardiovascular diseases, diabetes, and cancers [ 1–3 ]. and mortality from cardiovascular diseases [5].”
BackgroundPatients with unstable angina pectoris show an increased frequency of the Fc gamma RIIa R131 allele
Raaz‐Schrauder, D., Ekici, A. B., Munoz, L. E., Klinghammer, L., Voll, R. E., Leusen, J. H. W., van de Winkel, J. G. J., Reis, A., Schett, G. A., Garlichs, C. D., et al. (2012) · Autoimmunity · doi:10.3109/08916934.2012.682665 · Cited by 10
“It would thus seem plausible that genotyping identifies patients with CAD, who may benefit most from antiinflammatory therapy [47].”
BackgroundHuang, R., Quan, J., Su, B., Cai, C., Cai, S., Chen, Y., Mou, Z., Zhou, P., Ma, D., & Cui, X. (2022) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2022.131583 · Cited by 10
Acute Phase Reactants and the Concept of Inflammation
Saxena, A., & Cronstein, B. N. (2013) · Elsevier eBooks · doi:10.1016/b978-1-4377-1738-9.00057-8 · Cited by 16
Goda, T., & Miyahara, Y. (2017) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2017.11.036 · Cited by 11
Synthetic Peptide Libraries: From Random Mixtures to In Vivo Testing
Sandomenico, A., Caporale, A., Doti, N., Cross, S., Cruciani, G., Chambery, A., Falco, S. D., & Ruvo, M. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867325666180716110833 · Cited by 10
Amyloid Beta Peptide (Aβ1-42) Reverses the Cholinergic Control of Monocytic IL-1β Release
Richter, K., Ogiemwonyi‐Schaefer, R., Wilker, S., Chaveiro, A. I., Agné, A. M., Hecker, M., Reichert, M., Amati, A., Schlüter, K., Manzini, I., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9092887 · Cited by 10
“Interestingly, PC is a ligand of the pentraxin C-reactive protein (CRP), an acute phase protein present in human blood that is a widely used clinical marker for inflammation [9,10].”
BackgroundSigal, L. H. (2007) · JCR Journal of Clinical Rheumatology · doi:10.1097/rhu.0b013e31806548b5 · Cited by 12
Gastroesophageal reflux disease and non-digestive tract diseases
Chen, Y. (2015) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/17474124.2015.1012495 · Cited by 10
“speculated that CRP may directly affect atrium structure via the activation of serum complement [7].”
BackgroundSavarese, G., Rosano, G. M. C., Parente, A., D’Amore, C., Reiner, M. F., Camici, G. G., Trimarco, B., & Filardi, P. P. (2014) · International Journal of Cardiology · doi:10.1016/j.ijcard.2014.09.028 · Cited by 10
“Interestingly, specific inhibition of CRP reduced infarct size and left ventricular dysfunction in an experimental rat model of CRP-induced infarction [45].”
BackgroundBeyond the Biomarker: Monomeric CRP as a Driver of Multisystem Pathology in Rheumatoid Arthritis
Lazarut‐Nistor, A., & SLEVIN, M. A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26178227 · Cited by 10
“Despite this, the finding suggests that targeting CRP could be a promising treatment for reducing tissue damage in heart attacks, strokes, and other inflammatory or tissue-damaging conditions [95].”
Kiefer, J., Zeller, J., Schneider, L. A., Thomé, J., McFadyen, J. D., Hoerbrand, I. A., Lang, F., Deiss, E., Bogner, B., Schaefer, A.-L., et al. (2024) · Journal of Advanced Research · doi:10.1016/j.jare.2024.07.007 · Cited by 10
“Previous studies showed that human pCRP dissociates to pCRP*/ mCRP in disturbed rat tissue and displays similar pro-inflammatory properties in rats by activating rat complement [13,28,30,68].”
Conserved Domains, Conserved Residues, and Surface Cavities of C-reactive Protein (CRP)
Kumar, S. V., Ravunny, R. K., & Chakraborty, C. (2011) · Applied Biochemistry and Biotechnology · doi:10.1007/s12010-011-9270-7 · Cited by 9
C-Reactive Protein, Statins and the Risk of Vascular Events: A Better Understanding
Bikdeli, B. (2011) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-011-6323-7 · Cited by 12
“A recent animal model study suggested that application of an inhibitor of calciumdependent binding of CRP to phosphocholine can reduce the infarct size in rats with induced myocardial infarction to whom high doses of human CRP had been injected [ 32 ].”
BackgroundSchneider, M. P., Leusen, J. H. W., i, M. H., Garlichs, C. D., Amann, K., John, S., & Schmieder, R. E. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.07.009 · Cited by 9
Neckář, J., Alánová, P., Olejníčková, V., Papoušek, F., Hejnová, L., Šilhavý, J., Behuliak, M., Bencze, M., Hrdlička, J., Vecka, M., et al. (2021) · Clinical Science · doi:10.1042/cs20210648 · Cited by 10
“In rodents, CRP is not an acute-phase reactant and their CRP does not activate complement [5].”
BackgroundAlkouri, A., Cybularz, M., Mierke, J., Nowack, T., Biedermann, J., Ulbrich, S., Fischer, J., Heidrich, F. M., Jellinghaus, S., Speiser, U., et al. (2022) · Biomarkers · doi:10.1080/1354750x.2022.2040591 · Cited by 10
“In addition to its clinical role as a sensitive marker of inflammation, more and more data demonstrated that CRP could act as a direct mediator of inflammation and immune response (Pepys et al. 2006).”
BackgroundKumaresan, P. R., Devaraj, S., Huang, W., Lau, E. Y., Liu, R., Lam, K. S., & Jialal, I. (2013) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2012.0123 · Cited by 9
“7 In a small study, they demonstrated that administration of this compound to rats completely abrogated the increased morbidity, mortality, and infarct size experienced after coronary ligation by rats receiving human CRP alone.”
The effect of C-reactive protein deposition on myocardium with ischaemia–reperfusion injury in rats
Oh, S. J., Kim, E. N., Kim, C. J., Choi, J. S., & Kim, K. (2017) · Interactive Cardiovascular and Thoracic Surgery · doi:10.1093/icvts/ivx107 · Cited by 11
“They used 1,6-bis(phosphocholine)-hexane as an inhibitor of CRP conformational change to reduce myocardial infarct size [10, 12].”
MethodRai, H., Reddi, R., Coughlan, J. J., Durand, R., O’Callaghan, D., Colleran, R., & Byrne, R. A. (2025) · Health Science Reports · doi:10.1002/hsr2.70757 · Cited by 8
Wang, Y., Chen, W., Ding, S., Wang, W., & Wang, C. (2023) · Developmental & Comparative Immunology · doi:10.1016/j.dci.2023.105064 · Cited by 8
Diepenhorst, G. M. P., de Graaf, W., Niessen, H. W. M., van Vliet, A. K., Hack, C. E., & van Gulik, T. M. (2014) · European Surgical Research · doi:10.1159/000360474 · Cited by 8
Effects of a cytokine inhibitor, JTE-607, on the response to endotoxin in healthy human volunteers
Borozdenkova, S., Mant, T., Allen, E., Pu, K., Hoshino, S., & Jurčević, S. (2011) · International Immunopharmacology · doi:10.1016/j.intimp.2011.07.013 · Cited by 8
Pentraxins: The L-Type Lectins and the C-Reactive Protein as a Cardiovascular Risk
Gupta, G. (2012) · Springer eBooks · doi:10.1007/978-3-7091-1065-2_8 · Cited by 8
Lawlor, D. A., Timpson, N. J., Harbord, R. M., Ebrahim, S. B. J., & Smith, G. D. (2007) · JAMA · doi:10.1001/jama.297.12.1317-a · Cited by 8
Eikelboom, J. W., & O'Donnell, M. J. (2007) · JAMA · doi:10.1001/jama.297.1.91 · Cited by 8
La proteína C reactiva como blanco terapéutico en la prevención cardiovascular: ¿ficción o realidad?
Heres-Álvarez, F. D. L. C., & Peix-González, A. T. (2011) · Revista Española de Cardiología Suplementos · doi:10.1016/s1131-3587(11)15006-2 · Cited by 11
Depressive and anxiety symptoms among patients with inflammatory bowel diseases
Bielińska, J., Liebert, A., Lesiewska, N., Bieliński, M. K., Mieczkowski, A., Sopońska-Brzoszczyk, P., Brzoszczyk, B., Długosz, D., Guenter, W., Borkowska, A., et al. (2017) · Medical Research Journal · doi:10.5603/mrj.2017.0002 · Cited by 7
“Literature data also suggests that apart from being an inflammatory marker, CRP should also be regarded as an inflammatory mediator holding pro-thrombotic and pro-apoptotic properties [10–14].”
BackgroundZamani, B., Golabchi, A., Ghadakkar, N., & Motedayyen, H. (2022) · Journal of Immunoassay and Immunochemistry · doi:10.1080/15321819.2022.2119866 · Cited by 7
“Several researches have concluded that CRP noticeably rises the extent of myocardial damage caused by ischemic injury in animals .([25,26]) Our study revealed that patients with STEMI had a higher level of hs-CRP than those with NSTE ACS.”
ResultSingh, R. P., & Pattnaik, A. K. (2024) · Pharmacognosy Magazine · doi:10.1177/09731296241228925 · Cited by 7
“The proteins selected for this study were PDB IDs 3QNT, 3MWD, and 1B09, each chosen for its relevance to our research objectives and downloaded from the RCSB protein bank (Chu et al., 2010; Pandit et al., 2000; Pepys et al., 2006).”
Vattipalli, K., Feikert, P., Brandigampala, S. M., & Prasad, S. (2010) · Nano LIFE · doi:10.1142/s1793984410000213 · Cited by 7
Li, X., Liu, X., Nie, S., Du, X., Lü, Q., Kang, J.-P., Dong, J., Gu, C., Huang, F.-J., Yu-jie, Z. H. O. U., et al. (2010) · Chinese Medical Journal · doi:10.3760/cma.j.issn.0366-6999.2010.13.003 · Cited by 7
Metadata
- Authors
- Pepys, M. B., Hirschfield, G. M., Tennent, G. A., Ruth Gallimore, J., Kahan, M. C., Bellotti, V., Hawkins, P. N., Myers, R. M., Smith, M. D., Polara, A., Cobb, A. J. A., Ley, S. V., Andrew Aquilina, J., Robinson, C. V., Sharif, I., Gray, G. A., Sabin, C. A., Jenvey, M. C., Kolstoe, S. E., Thompson, D., & Wood, S. P.
- Affiliations
- The Royal Free Hospital (GB)
- University of Pavia (IT)
- University of Cambridge (GB)
- University of Edinburgh (GB)
- University of Southampton (GB)
- University of Sussex (GB)
- Corresponding author
- Pepys, Mark B.
- ORCID
- Venue
- Nature
- Published
- 2006-04
- Volume
- 440
- Issue
- 7088
- Pages
- 1217-1221
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2080883999
- Cited by
- 672
- References
- 31
- Citations by year
- 2026: 6 · 2025: 17 · 2024: 19 · 2023: 30 · 2022: 27 · 2021: 28 · 2020: 32 · 2019: 21 · 2018: 23 · 2017: 20 · 2016: 23 · 2015: 16 · 2014: 35 · 2013: 30 · 2012: 40
- FWCI
- 26.49
- Type
- journal article
- Language
- en
- Open access
- green
- figshare.com
- Licence
- cc-by
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- CentAUR (University of Reading) (acceptedVersion)
- ePrints Soton (University of Southampton) (acceptedVersion)
- Research Online (University of Wollongong) (submittedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- Figshare (submittedVersion)
- Funders
- Wellcome Trust
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Biomarkers in Disease Mechanisms
- Life Sciences › Immunology and Microbiology › Immunology › Complement system in diseases
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Fibrosis and Remodeling
- Keywords
- C-reactive protein, acute myocardial infarction, complement activation, cardioprotection, infarct size, neuroprotection, cerebral ischemia, small-molecule drug design, acute phase proteins, inflammation, stroke, drug repurposing
- MeSH terms
- Animals, C-Reactive Protein, Cardiovascular Diseases, Complement System Proteins, Hexanes, Humans, Male, Models, Molecular, Molecular Conformation, Myocardial Infarction, Phosphorylcholine, Drug Design, Rats, Wistar, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.